RECURSION PHARMACEUTICALS-A

Gibson Christopher’s Rule 10b5‑1 trade shows steady confidence in Recursion Pharmaceuticals‑A’s AI‑driven drug pipeline, amid modest share dip but sharp investor interest.

Insider selling at Recursion Pharmaceuticals is measured and routine, with director Blake selling 30k shares at $3.68, reflecting strategic rebalancing without hurting growth prospects.